• EZ Cap™ Cy5 EGFP mRNA (5-moUTP) for Advanced mRNA Delivery

  2026-05-13

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) streamlines dual-fluorescence mRNA delivery assays, letting researchers quantify uptake and translation efficiency in real time. Its immune-evasive chemistry and robust Cap 1 structure provide a decisive edge for nanoparticle validation, gene regulation studies, and troubleshooting transfection protocols.

• Fluorouracil in Advanced Colon Cancer Research: Molecular In

  2026-05-13

  Explore the molecular mechanisms and assay optimization of Fluorouracil (5-Fluorouracil) in colon cancer research. Discover how genomic heterogeneity impacts drug response, with practical guidance for experimental design and interpretation.

• HR Pathway Profiling Predicts Olaparib Sensitivity in Mesoth

  2026-05-12

  Borchert et al. (2019) identified that gene expression profiles reflecting homologous recombination repair (HRR) deficiencies—'BRCAness'—are present in a subset of malignant pleural mesothelioma (MPM) cases, correlating with enhanced sensitivity to PARP inhibition by olaparib. Their findings point to novel stratification strategies and combinatorial chemotherapy approaches in MPM, potentially improving outcomes through precision targeting of DNA repair vulnerabilities.

• Selective FGFR1 Inhibition in Neuronal Survival: Insights fr

  2026-05-12

  This study establishes PD 173074 as a highly selective, nanomolar-potency FGFR1 inhibitor that antagonizes FGF-2-mediated neurotrophic and neurotropic effects in neurons. The findings offer a robust experimental tool for dissecting FGF signaling in neural development and disease models without off-target disruption of other neurotrophic pathways.

• Applied Workflows with Enhanced ECL Chemiluminescent Detecti

  2026-05-11

  The ECL Chemiluminescent Substrate Detection Kit (Enhanced) from APExBIO delivers unmatched sensitivity and prolonged signal for western blot chemiluminescence detection, simplifying workflows for low-abundance protein targets. This article translates cutting-edge research into actionable protocol enhancements, troubleshooting tips, and comparative insights for advanced antibody detection assays.

• Norovirus Selectively Exploits NINJ1 for Viral Protein Secre

  2026-05-11

  Song et al. reveal that murine norovirus hijacks the host protein NINJ1 to enable selective secretion of the viral NS1 protein through a non-canonical pathway. This study advances understanding of regulated cell death and viral immune evasion, highlighting mechanistic links relevant for cell biology and pathogen-host interaction research.

• Pexmetinib (ARRY-614): Enhancing Cytokine Inhibition Workflo

  2026-05-10

  Pexmetinib (ARRY-614) empowers researchers to dissect inflammatory and angiogenic pathways with dual kinase inhibition, robust cytokine suppression, and new conformational insights. This guide translates recent structural advances and best-practice protocols into actionable, reproducible results for myelodysplastic syndromes and inflammation research.

• DMH-1 Enables Precision in BMP Pathway Control for Translati

  2026-05-09

  Explore how DMH-1, a selective ALK2 inhibitor, unlocks tunable control of BMP signaling for organoid engineering and non-small cell lung cancer research. This thought-leadership article synthesizes cutting-edge mechanistic insights, recent human organoid system advances, and actionable protocol guidance for translational researchers, referencing APExBIO's DMH-1 and the latest literature.

• Octanoic Acid Nutrition Modulates IBD via PPARγ/STAT-1/STAT-

  2026-05-08

  This study demonstrates that octanoic acid-rich enteral nutrition alleviates inflammatory bowel disease by regulating intestinal macrophage polarization through the PPARγ/STAT-1/STAT-6 signaling axis. The findings highlight the mechanistic role of PPARγ in immune modulation and offer a molecular basis for nutritional interventions in IBD management.

• T-5224: Applied Workflows for C-Fos/AP-1 Inhibition in Infla

  2026-05-08

  T-5224, a selective C-Fos/AP-1 inhibitor from APExBIO, transforms arthritis and neuroinflammation research by enabling precise modulation of MMPs and pro-inflammatory cytokines. With robust in vitro and in vivo validation, it delivers reproducible results in models where AP-1 signaling drives pathology.

• Fluorouracil in Solid Tumor Research: Protocols & Optimizati

  2026-05-07

  Fluorouracil (Adrucil) from APExBIO delivers reproducible inhibition of DNA replication in solid tumor models, with validated protocols supporting colon and breast cancer research. This guide translates mechanistic insights and recent breakthroughs into stepwise workflows and troubleshooting strategies that maximize data quality and translational impact.

• Rapid Modulation of Depression-like Behaviors via PrLGlu/avB

  2026-05-07

  A recent study reveals that activating the PrLGlu/avBNSTGABA neural circuit in male mice swiftly alleviates depression-like behaviors, highlighting the circuit’s mechanistic role and its potential as a therapeutic target. This work leverages chemogenetic and optogenetic tools to dissect circuit function, providing valuable insights for translational neuroscience and circuit-level intervention strategies.

• Ceramide-Mediated Lipid Remodeling in Fish Nodavirus Infecti

  2026-05-06

  This study uses comprehensive lipidomic profiling to reveal how ceramide metabolism is manipulated by red-spotted grouper nervous necrosis virus (RGNNV) to promote viral replication in fish cells. By identifying ceramide synthesis as a pro-viral mediator—especially via autophagy—this research provides a mechanistic basis for targeting sphingolipid pathways in antiviral strategies.

• Patient-Derived Gastric Cancer Assembloids: Modeling Microen

  2026-05-06

  The referenced study introduces a novel gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations, better recapitulating patient tumor heterogeneity and microenvironment. This innovation enables more physiologically relevant preclinical drug testing and advances the understanding of stromal contributions to drug resistance and personalized therapy design.

• Optimizing BET Bromodomain Assays with (-)-JQ1 Stereoisomer

  2026-05-05

  (-)-JQ1 is a rigorously validated, stereospecific negative control enabling precise dissection of BET bromodomain functions in epigenetics and cancer biology research. This article details practical workflows, troubleshooting strategies, and protocol enhancements for researchers leveraging (-)-JQ1 to maximize assay specificity and data reliability.

15067 records 1/1005 page Next 12345 下5页 Last page